Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen to Use Proteomics Technology to Develop Cancer Diagnostics with Johns Hopkins

NEW YORK, Nov 29 – ProteinChip-maker Ciphergen Biosystems said Wednesday that it would collaborate with Johns Hopkins University School of Medicine to develop proteomic diagnostic tests for cancer.

Ciphergen will use its ProteinChip System to discover and validate protein biomarkers in cancer serum samples provided by Johns Hopkins. The university will also provide the clinical expertise of its physicians and scientists.

Protein biomarkers may help doctors detect cancers earlier and distinguish forms of the disease. The markers may also prove to be protein drug candidates or point researchers toward potential drug targets.

Currently most diagnostic tests rely on a single marker. “The goal here is to come up with multi-marker diagnostic tests for disease that will have far more discriminating power,” said Matthew Hogan, CFO at Ciphergen. “Potentially you could diagnose a disease in an earlier state, but certainly you could do it more reliably.”

Hogan would not predict when the diagnostic tests would hit the market.

Ciphergen will provide financial support and technical assistance and would retain commercial rights to discoveries made through the collaboration.

Further financial terms of the deal were not disclosed .
The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.